Oncternal Therapeutics (NASDAQ:ONCT) reported quarterly losses of $(2.83) per share which beat the analyst consensus estimate of $(2.88) by 1.74 percent. This is a 27.99 percent increase over losses of $(3.93) per share from the same period last year. The company reported quarterly sales of $569.000 thousand which beat the analyst consensus estimate of $176.667 thousand by 222.08 percent. This is a 180.30 percent increase over sales of $203.000 thousand the same period last year.
Oncternal Therapeutics Q1 2024 GAAP EPS $(2.83) Beats $(2.88) Estimate, Sales $569.000K Beat $176.667K Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.